| Press releases

Formycon appoints biotech expert Professor Johannes Buchner to the Advisory Board

Formycon is underpinning its claim to scientific excellence by appointing Johannes Buchner, professor in Biotechnology at the Technical University of Munich and President of the German Society for Biochemistry and Molecular Biology, to its Advisory Board.


8th Biosimilars Congregation

Speaker: Carsten Brockmeyer, PhD
Date: March 8 – 9, 2016
Location: London, UK

Financial reports

Annual report 2014

Published on May 19, 2015

  • buchner_de
  • slider02
  • slider03
  • slider04
  • slider05
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.